Catriona Byrne

Statistics

Publications

Citations

1.4K

H-Index

Active since

2005

Affiliations

Dana-Farber Cancer Institute(Current)

Millennium Engineering and Integration (United States)

National and Kapodistrian University of Athens

Medical University of Lublin

Medical University of Warsaw

Catriona Byrne is an author at Dana-Farber Cancer Institute specializing in hematologic malignancy pharmacotherapy, pharmacotherapy, and hematologic malignancy therapy.

ORCID

Publications per year

2005–2021

Publications

Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study

Asher Chanan‐Khan, Kena C. Miller, Laurie Musial et al. · Journal of Clinical Oncology · 2006 · 409 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

Michael Wang, Luis Fayad, Nicolaus A. Wagner‐Bartak et al. · The Lancet Oncology · 2012 · 297 citations

Medicine, Oncology, Pharmacotherapy +16

Lenalidomide therapy in myelofibrosis with myeloid metaplasia

Ayalew Tefferi, Jörge E. Cortes, Srđan Verstovšek et al. · Blood · 2006 · 252 citations · Full text

Medicine, Hematology, Oncology +13

Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma

Paul G. Richardson, Albert Oriol, Alessandra Larocca et al. · Journal of Clinical Oncology · 2020 · 155 citations · Full text

Medicine, Oncology, Pharmacology +14

Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1–2 study

Paul G. Richardson, Sara Bringhen, Peter M. Voorhees et al. · The Lancet Haematology · 2020 · 88 citations

Pharmacy, Oncology, Pharmacotherapy +11

1–5 of 18